TGFB1 and cancer: Combination therapies that target global deposition of ECM, such as TGFβ inhibitors (Mariathasan et al., 2018; Tauriello et al., 2018), or specific ECM components, for example in situ degradation of hyaluronic acid, can improve therapy response in murine cancer models (Hingorani et al., 2018).